We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
- Authors
Giaccone, Giuseppe; Herbst, Roy S; Manegold, Christian; Scagliotti, Giorgio; Rosell, Rafael; Miller, Vincent; Natale, Ronald B; Schiller, Joan H; Von Pawel, Joachim; Pluzanska, Anna; Gatzemeier, Ulrich; Grous, John; Ochs, Judith S; Averbuch, Steven D; Wolf, Michael K; Rennie, Pamela; Fandi, Abderrahim; Johnson, David H
- Abstract
The purpose of this study was to determine whether the addition of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE) to standard first-line gemcitabine and cisplatin provides clinical benefit over gemcitabine and cisplatin alone in patients with advanced or metastatic non-small-cell lung cancer (NSCLC). Gefitinib has demonstrated encouraging efficacy in advanced NSCLC in phase II trials in pretreated patients, and a phase I trial of gefitinib in combination with gemcitabine and cisplatin showed favorable tolerability.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Vol 22, Issue 5, p777
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2004.08.001